Global Attention Deficit Hyperactivity Disorder Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Attention Deficit Hyperactivity Disorder Market Research Report 2024
Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age.
According to MRAResearch’s new survey, global Attention Deficit Hyperactivity Disorder market is projected to reach US$ 15440 million in 2033, increasing from US$ 12240 million in 2022, with the CAGR of 3.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Attention Deficit Hyperactivity Disorder market research.
There are two main types of drugs used to treat ADHDstimulants and non-stimulants
The main manufacturers of stimulants are in Europe and America, and the main manufacturers of non-stimulants are in China.
ADHD is mainly used in hospital pharmacies and retail pharmacies. Among them, in 2020, the market share of retail pharmacies accounted for approximately 83%
Takeda has the highest market share in ADHD by major global companies, which is much higher than the market share of other companies, about 21% in 2022.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Attention Deficit Hyperactivity Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Eli Lilly
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt
Hisamitsu
Johnson & Johnson
Purdue Parma
Segment by Type
Stimulants Drugs
Non-stimulants Drugs
Pediatric
Adolescent
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Attention Deficit Hyperactivity Disorder report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Attention Deficit Hyperactivity Disorder market is projected to reach US$ 15440 million in 2033, increasing from US$ 12240 million in 2022, with the CAGR of 3.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Attention Deficit Hyperactivity Disorder market research.
There are two main types of drugs used to treat ADHDstimulants and non-stimulants
The main manufacturers of stimulants are in Europe and America, and the main manufacturers of non-stimulants are in China.
ADHD is mainly used in hospital pharmacies and retail pharmacies. Among them, in 2020, the market share of retail pharmacies accounted for approximately 83%
Takeda has the highest market share in ADHD by major global companies, which is much higher than the market share of other companies, about 21% in 2022.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Attention Deficit Hyperactivity Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eli Lilly
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt
Hisamitsu
Johnson & Johnson
Purdue Parma
Segment by Type
Stimulants Drugs
Non-stimulants Drugs
Segment by Application
Pediatric
Adolescent
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Attention Deficit Hyperactivity Disorder report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source